After the first in-person Americas Committee for Treatment and Research in MS Forum since the onset of the COVID-19 pandemic, a variety of experts in the care of MS spoke to some of the research highlights, lingering needs, and hot topics in the field.
We ask 3 pediatricians about new findings, showing that the Pfizer/BioNTech vaccine is less effective in younger children (5 to 11 years) than in older ones (12 to 17 years).
Experts highlight some of the key takeaways and most intriguing presentations from the 39th Annual Miami Breast Cancer Conference®.
In bringing together national leaders from across the healthcare spectrum, this year’s virtual V-Bid Summit will address the opportunities and challenges regarding strategies to reduce health care disparities and enhance equity. Dr Mark Fendrick, director of the University of Michigan Center for Value-Based Insurance Design, spoke with The American Journal of Managed Care® on the key discussions to be held at the meeting, with panelists Katy Spangler, principal at Spangler Strategies, and Dr Dora Hughes, chief medical officer at the CMS Innovation Center, also previewing their talks as well.
Oncology Nursing News® asked oncology nurses from across the country if they are still interested in hearing and reading about COVID-19.
The notion that the key to obesity management is to “eat less, move more,” is a deeply rooted cultural belief that can still be resistant to the current truth that obesity is a chronic, relapsing disease. Obesity medicine experts confirm that while dietary change and exercise are essential to the success of a weight management program, used alone they will not sustain meaningful weight loss for persons with overweight, obesity, or severe obesity. Enter the generation of new drugs that target the specific underlying physiology of obesity and work along with diet, exercise, and other interventions to augment and sustain weight loss. Editors at Patient Care Online spoke with leading obesity medicine investigators about how the new medications can be integrated into primary care where patients are seen first and most consistently as they struggle against the disease of obesity.
March is Kidney Cancer Awareness month and a good time to reflect on recent advancements in the treatment of patients with renal cell carcinoma. Recent years have brought numerous new therapies and combination regimens to this space, with breakthrough research ongoing. Following the recent 2022 Genitourinary Cancers Symposium, Chung-Han Lee, MD, PhD, Daniel M. Geynisman, MD, and Toni K. Choueiri, MD, spoke with editors at CancerNetwork® to discuss recent advances that have the potential to significantly impact care and ongoing trials that clinicians should be aware of.
In recognition of the recent celebration for Rare Disease Day, a number of experts in the care of rare diseases spoke to some of the advances and challenges experienced by the field in the past few years. They include: Hong Sun, MD, PhD, on the importance of Rare Disease Day; Sabrina Paganoni, MD, PhD, on the incremental advances being made in ALS drug development; Bruce Cree, MD, PhD, on the need for more patient education on neuromyelitis optica spectrum disorder; James Howard, MD, on the potential for combination approaches to generalized myasthenia gravis; and Tahseen Mozaffar, MD, on the potential of gene therapies for Pompe disease.
Experts discusses some of the key takeaways and most intriguing data to emerge from the 2022 Genitourinary Cancers Symposium.
This episode discusses the current state of the pharmacy technician role, how COVID-19 changed the perception of pharmacy technicians, and advice for technicians who wish to advance their roles and responsibilities in the pharmacy.
On this week’s episode of Behind the Science, Contemporary OBGYN sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Editors of Managed Healthcare Executive spoke with four healthcare professionals about the relationship between COVID-19 and obesity. The professionals were asked “at what degree is obesity a risk factor for severe COVID-19 and what are the reasons for obesity increasing the risk?” Each gave their individual views on the matter.
Several experts join Behind the Science to answer the question: Why is gout is so underrepresented in rheumatology research?
On January 28, the FDA approved faricimab (Vabysmo) for the treatment of adults with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME). The new approval for the intravitreal-injected bispecific antibody therapy is the first granted to a drug with its targeting pathways, deviating from the popular standard-of-care anti-VEGF therapy drug class for these two conditions—the leading causes of irreversible vision loss in the US. It also comes at a time when many ophthalmologists are seeking means to improve treatment durability and extended time between regimens of intravitreal injection therapy for their patients, who are generally burdened by the administration process and are prone to high risk of treatment discontinuation—and, as such, eventual blindness.
In conversations with NeurologyLive on the floor of the American Epilepsy Society’s Annual Meeting, 5 experts in epilepsy and seizure disorders shared their insight into their biggest takeaway from the annual meeting—which was in-person for the first time since 2019.
Long-acting injectables are being studied for both HIV care and prevention and could help in changing the treatment paradigm from a daily oral regimen to a once monthly or even every 2 month injection for therapy. They have shown promise as a potential alternative to people dealing with pill fatigue, stigma, and quality of life issues associated with daily oral therapy. Clinicians offer insights into what medical community is doing right in this area where the challenges remain.
With an influx of novel agents hitting the oncology scene across both breast and hematologic spheres, it can become more complicated to differentiate between agent-related patient education and administration details. Therefore, Oncology Nursing News® spoke with 4 oncologists who presented at either the 2021 San Antonio Breast Cancer Symposium of the 63rd American Society of Hematology Annual Meeting & Exposition about the main findings from their presentations and nurse-specific considerations regarding the experimental agents.
In this episode of Behind the Science, we hear from optometrists on what they wish they knew when starting out their optometric careers.
3 psychiatrists answer the question: Do you believe the medical profession adequately explores gender issues?
In a webcast discussion, Pharmacy Times interviewed a panel of experts on the future of psychedelic medicine and the role of the pharmacy in that future. Specifically, the experts discuss psychedelic medicine access and what would different distribution models could look like to provide the best access points for patients. Additionally, the experts touch on who they think should be authorized to either administer or obtain psychedelic medicine and if the administration of psychedelic drugs should only be in the hands of certain health care professionals, such as psychiatrists.
Robert Popovian, PharmD, MS, chief science policy officer at Global Healthy Living Foundation, and Bret Jackson, president of the Economic Alliance for Michigan, join Behind the Science to discuss the strength of multiple policy initiatives that have been tested at the federal and state level to get biosimilars into the hands of patients who need them.
A panel of oncologists join Behind the Science to review the data and discuss the impact of 4 recent FDA approvals in oncology.
Linda Dickey, RN, MPH, CIC, CPHQ, FAPIC, is the new president of the Association for Professionals in Infection Control and Epidemiology—APIC. She talks about what it takes to become an infection preventionist, and the challenges the infection preventionist field faces. For instance. APIC is pushing to have states mandate that anybody working with the title infection preventionist be certified as such, and that nursing homes must have a full-time IP on staff.
Several doctors speak about their biggest takeaways and the most important abstracts presented at the 2021 ASH Annual Meeting and Exposition.
Tony Makarich, PharmD and vice president of clinical services at Catalyst Health Rx, joined to discuss the benefits for health care providers of a relationship and team-based pharmacy model. He dives into Catalyst Health Rx's current pharmacy model that values relationships with convenience for medication home delivery and assures that providers do not lose sight of the impact they have on their patients.
A panel of urologists share the biggest takeaways from SUO 2021.
With 2022 bringing a new chapter for cancer research, many physicians and researchers are looking forward to new developments in the coming year. CURE asked several of them to share what they’re excited about or hoping to see in 2022.
As we put 2021 behind us and look ahead at 2022, it promises to be another year full of advancements and new discoveries in the field of cardiometabolic health. With the COVID-19 pandemic placing cardiometabolic health in a spotlight, Practical Cardiology and Endocrinology Network assistant managing editor Patrick Campbell polled his recent interview guests with the simple question: what are they most looking forward to in 2022.
